Valproate-treated patients presenting with altered mental status are at risk for which metabolic complication?

Valproate-treated patients presenting with altered mental status are at risk for which metabolic complication?

• A. Hypoglycemia
• B. Hyperammonemia
• C. Hypophosphatemia
• D. Hyperkalemia

Answer: (C)

Hyperammonemia is the metabolic complication to watch for in valproate-treated patients who present with altered mental status. Valproic acid can impair the liver’s urea cycle, lowering the production of N-acetylglutamate, an essential activator of carbamoyl phosphate synthetase I. This reduces ammonia clearance, allowing ammonia to accumulate in the blood and cause encephalopathy. The mental status changes—confusion, lethargy, or coma—often reflect this rising ammonia level. Mechanisms can be amplified by valproate-related hepatic injury or carnitine deficiency, both of which further impair ammonia detoxification. Management centers on stopping valproate, addressing the hyperammonemia (for example, lactulose or rifaximin to reduce intestinal ammonia production), and considering L-carnitine supplementation if indicated. Hypoglycemia, hypophosphatemia, and hyperkalemia are not the classic drivers of this presentation in the valproate context.

Hyperammonemia is the metabolic complication to watch for in valproate-treated patients who present with altered mental status. Valproic acid can impair the liver’s urea cycle, lowering the production of N-acetylglutamate, an essential activator of carbamoyl phosphate synthetase I. This reduces ammonia clearance, allowing ammonia to accumulate in the blood and cause encephalopathy. The mental status changes—confusion, lethargy, or coma—often reflect this rising ammonia level. Mechanisms can be amplified by valproate-related hepatic injury or carnitine deficiency, both of which further impair ammonia detoxification. Management centers on stopping valproate, addressing the hyperammonemia (for example, lactulose or rifaximin to reduce intestinal ammonia production), and considering L-carnitine supplementation if indicated. Hypoglycemia, hypophosphatemia, and hyperkalemia are not the classic drivers of this presentation in the valproate context.